Praktické lékárenství – 1/2019

www.praktickelekarenstvi.cz / Prakt. lékáren. 2019; 15(1e): e3–e14 / PRAKTICKÉ LÉKÁRENSTVÍ e13 MEDICAMENTA NOVA BREXPIPRAZOL LITERATURA 1. Češková E. Postavení aripiprazolu v klinické praxi. Čes a slov Psychiatrie 2011; 107: 110–114. 2. Mohr P, Kopeček M, Brunovský M, et al. Kariprazin in Klinická psychofarmakologie.Max- dorf, 2017, pp 161–164. 3. Ceskova E, Silhan P. Novel treatment options in depression and psychosis. Neuropsychi- atr Dis Treat 2018; 14: 741–747. 4. Citrome L. The ABC’s of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract 2015; 69: 1211–1220. 5. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 589–604. 6. Mohr P, Kopeček M, Brunovský M, et al. Brexpiprazol, in Klinická psychofarmakologie. Maxdorf, 2017, pp 135–138. 7. Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr 2016; 21:1–6. 8. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) and aripi- prazole in adult patients with acute schizophrenia: results from a randomized, explorato- ry study. Int Clin Psychopharmacol 2016; 31: 192–201. 9. Citrome L. Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder. Absolute Risk Increase and Number Needed to Harm. J Clin Psychopharmacol 2017; 37: 138–147. 10. Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. Ment Health Clin 2017; 7: 246–254. 11. Polcwiartek C, Sneider B, Graff C, et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psy- chopharmacology (Berl) 2015; 232: 3297–3308. 12. Chattopadhyay A, Frey S,Green G. Bifeprunox versus placebo for schizophrenia. Coch- rane Database Syst Rev 2016; 10: CD012029. 13. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 605–614. 14. Rexulti (brexpiprazole) [product information]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd 2015. 15. I. OPDC: PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia. [cited 2018 Nov 11]. Available from: http://clinicaltrials.gov/show/NCT01854944 16. Correll CU, Skuban A, Ouyang J, et al. Efficacy and Safety of Brexpiprazole for the Tre- atment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry 2015; 172: 870–880. 17. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, contro- lled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schi- zophrenia. Schizophr Res 2015; 164: 127–135. 18. Ishigooka J, Iwashita S,Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 2018; 72: 692–700. 19. Kishi T, Oya K, Matsui Y, et al. Comparison of the efficacy and safety of 4 and 2mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo- -controlled trials. Neuropsychiatr Dis Treat 2018; 14: 2519–2530. 20. Fleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and Safety of Brexpiprazole (OPC- 34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. Int J Neuropsychopharmacol 2017; 20: 11–21. 21. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpipra- zole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled stu- dy in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224–1231. 22. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for pa- tients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76: 1232–1240. 23. Hobart M, Skuban A, Zhang P, et al. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adul- ts With Major Depressive Disorder. J Clin Psychiatry 2018; 79. 24. Bauer M, Hefting N, Lindsten A, et al: A randomised, placebo-controlled 24-week stu- dy evaluating adjunctive brexpiprazole in patients with major depressive disorder. Acta Neuropsychiatr 2018; 1–9. 25. Lepola U, Hefting N, Zhang D, et al. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study. Int J Ge- riatr Psychiatry 2018; 33: 1403–1410. 26. Otsuka Pharmaceutical Development & Commercialization I. A study of two fixed-doses of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer’s type [Internet] Bethesda (MD): National Library of Medicine (US); 2000 [ci- ted 2018 Nov 11]. Available from: http://clinicaltrials.gov/show/NCT01862640; 27. Rexulti, brexpiprazole (summary of product characteristics). the European Medicines Agency http://www.ema.europa.eu. 2018.